Genovis
19.40 SEK
+2.54 %
1,631 following
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Genovis
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 60.5 | 61.0 | 93.0 | 102.4 | 158.2 | 130.4 | 128.9 |
| growth-% | 0.8 % | 52.4 % | 10.1 % | 54.5 % | -17.6 % | -1.1 % | |
| EBITDA | 13.6 | 8.6 | 30.3 | 14.9 | 64.0 | 56.2 | 33.6 |
| EBIT | 10.1 | 3.1 | 24.5 | 8.3 | 54.2 | 45.7 | 21.3 |
| Profit before taxes | 9.7 | 2.1 | 24.6 | 8.0 | 54.9 | 46.3 | 26.8 |
| Net income | 9.6 | 6.4 | 24.8 | 11.2 | 61.5 | 32.9 | 23.5 |
| EPS | 0.15 | 0.10 | 0.38 | 0.19 | 0.94 | 0.50 | 0.36 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 22.4 % | 14.0 % | 32.6 % | 14.6 % | 40.4 % | 43.1 % | 26.0 % |
| EBIT-% | 16.6 % | 5.1 % | 26.4 % | 8.1 % | 34.3 % | 35.1 % | 16.5 % |
| ROE | 26.8 % | 7.4 % | 21.7 % | 8.9 % | 32.2 % | 14.4 % | 8.7 % |
| ROI | 19.5 % | 6.0 % | 17.5 % | 7.4 % | 21.3 % | 10.1 % | 6.2 % |